Personalis Stock

Personalis ROE

The Return on Equity (ROE) of Personalis (PSNL) as of Aug 21, 2026 is -31.12 %. In the previous year, Return on Equity (ROE) was -40.05 % — a change of -22.31% (higher).

ROE

-31.12 %

YoY

-22.31%

Last updated:

In 2026, Personalis's return on equity (ROE) was -31.12 %, a -22.31% increase from the -40.05 % ROE in the previous year.

Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

ROE Details

Decoding Personalis's Return on Equity (ROE)

Personalis's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Personalis's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Personalis's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Personalis’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Personalis stock

Return on Equity (ROE) of Personalis is -31.12 % in 2026.

Return on Equity (ROE) of Personalis changed from -40.05 % to -31.12 %, representing a -22.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Personalis since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Personalis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Personalis

All Key Metrics — Personalis